Columvi is a CD20xCD3 T-cell engaging bispecific antibody. Columvi was the first fixed-duration bispecific antibody to receive accelerated approval by the FDA and conditional marketing authorisation in Europe to treat people with R/R DLBCL after two or more lines of systemic therapy. Columvi is approved in more than 50 countries for 3L+ DLBCL.